Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis
Related Experiment Video
Updated: Feb 5, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Jonathan Massey1, Darren Plant2, Kimme Hyrich2,3
1Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK.
Abstract:
Rheumatoid arthritis (RA) is characterised by chronic synovial joint inflammation. Treatment has been revolutionised by tumour necrosis factor alpha inhibitors (TNFi) but each available drug shows a significant non-response rate. We conducted a genome-wide association study of 1752 UK RA TNFi-treated patients to identify predictors of change in the Disease Activity Score 28 (DAS28) and subcomponents over 3-6 months. The rs7195994 variant at the FTO gene locus was associated with infliximab response when looking at a change in the swollen joint count (SJC28) subcomponent (p = 9.74 × 10-9). Capture Hi-C data show chromatin interactions in GM12878 cells between rs2540767, in high linkage disequilibrium with rs7195994 (R2 = 0.9) and IRX3, a neighbouring gene of FTO. IRX3 encodes a transcription factor involved in adipocyte remodelling and is regarded as the obesity gene at the FTO locus. Importantly, the rs7195994 association remained significantly associated following adjustment for BMI. In addition, using capture Hi-C data we showed interactions between TNFi-response associated variants and 16 RA susceptibility variants.
Insights
Genetic variants near the FTO gene predict response to tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA) patients. The rs7195994 variant influences swollen joint count reduction, independent of BMI.
Area of Science:
- Genetics
- Immunology
- Rheumatology
Background:
- Rheumatoid arthritis (RA) involves chronic joint inflammation.
- Tumor necrosis factor alpha inhibitors (TNFi) revolutionized RA treatment.
- Significant non-response rates limit current TNFi efficacy.
Purpose of the Study:
- Identify genetic predictors of treatment response in RA patients receiving TNFi.
- Analyze changes in Disease Activity Score 28 (DAS28) and its components.
Main Methods:
- Genome-wide association study (GWAS) of 1752 UK RA patients treated with TNFi.
- Analysis of Disease Activity Score 28 (DAS28) changes over 3-6 months.
- Capture Hi-C data used to investigate chromatin interactions.
Main Results:
- The FTO gene locus variant rs7195994 associated with infliximab response (p=9.74×10⁻⁹) in swollen joint count (SJC28).
- rs7195994 is in high linkage disequilibrium with rs2540767, interacting with IRX3.
- Association remained significant after adjusting for Body Mass Index (BMI).
- TNFi-response variants interact with 16 RA susceptibility variants.
Conclusions:
- Genetic variations, specifically rs7195994 at the FTO locus, can predict TNFi treatment response in RA patients.
- IRX3, a gene near FTO, is implicated in RA treatment response.
- These findings may inform personalized medicine approaches for RA management.
More Related Videos
09:31Generation of Induced-pluripotent Stem Cells Using Fibroblast-like Synoviocytes Isolated from Joints of Rheumatoid Arthritis Patients
Published on: October 16, 2016
04:50Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Factors Affecting Drug Response: Overview
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Genomics